The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) (TeDIMO)

May 22, 2026 updated by: University Hospital, Grenoble
The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

220

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Grenoble, France
        • Recruiting
        • Chu Grenoble Alpes
        • Contact:
        • Principal Investigator:
          • Aurélie TRUFFOT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Participants in the MA group will be selected from among patients attending memory consultations at the CMRR at the CHU Grenoble-Alpes (active file within the department) or from among patients referred to the CMRR by a doctor not practicing at the CMRR (general practitioners or specialists such as neurologists). Healthy elderly participants will be recruited from among those accompanying patients being monitored at the CMRR.

Description

Inclusion criteria :

  • Alzheimer's disease:

    • Age ≥ 50 years and older
    • Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011.
    • Score 18≤ MMSE ≤26

  • Controls:

    • Age ≥ 50 years and older
    • MMSE score ≥ 26 For all subjects
    • No objection from the participant

Exclusion criteria

  • Alzheimer's disease:

    • Persons referred to in Articles L1121-5 to L1121-8 of the CSP

  • Controls:

    • Memory complaints
    • Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects
    • Significant neurological or psychiatric history
    • Taking psychotropic medication (neuroleptics)
    • Poor command of the French language, comprehension difficulties
    • Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.)
    • Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
People with Alzheimer Disease
Other: Identification and naming task
Task of identification and naming of landmarks and celebrities
Healthy elderly people
Other: Identification and naming task
Task of identification and naming of landmarks and celebrities

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference between the two groups in the identification and naming task involving famous landmarks
Time Frame: 1 month
show a significant difference in performance between the two groups in the identification and naming task involving famous landmarks
1 month

Secondary Outcome Measures

Outcome Measure
Time Frame
Development and standardization of a new tool for screening for naming disorders and visual identification of unique entities.
Time Frame: 5 years
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Grenoble

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 23, 2026

Primary Completion (Estimated)

February 1, 2031

Study Completion (Estimated)

February 1, 2032

Study Registration Dates

First Submitted

December 15, 2025

First Submitted That Met QC Criteria

January 19, 2026

First Posted (Actual)

January 26, 2026

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 22, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 38RC25.0190_TeDIMO
  • 2025-A01292-47 (Other Identifier: ID RCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer s Disease

Clinical Trials on Identification and naming task

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe